Tranexamic acid shows limited to no effectiveness for postpartum hemorrhage prevention in high-income countries
Background
Postpartum hemorrhage (PPH) remains the leading global cause of maternal morbidity and mortality, with incidence rising even in high-income countries (HICs). Tranexamic acid (TXA), an antifibrinolytic, has strong evidence for PPH management from low- and middle-income countries (LMICs). However, the direct applicability of these findings to HICs, where patient populations, risk factors, and existing obstetric care might differ, has been a significant knowledge gap. This review addresses the need to understand TXA's specific efficacy for PPH in HIC settings.
Study Design
This study conducted a comprehensive review of recent literature, specifically focusing on large randomized controlled trials (RCTs), to evaluate the use of Tranexamic acid (TXA) for the prevention and treatment of postpartum hemorrhage (PPH). The scope was explicitly limited to studies performed in high-income countries (HICs). The primary objective was to synthesize evidence regarding TXA's effectiveness in preventing PPH and to assess the availability of recent data on its use for PPH treatment within these specific geographic and economic settings.
Results
The review of recent large RCTs in HICs revealed that Tranexamic acid (TXA) demonstrated limited to no effectiveness for the prevention of postpartum hemorrhage (PPH). This finding contrasts significantly with the established benefits observed in low- and middle-income countries (LMICs), suggesting a potential disparity in efficacy across different healthcare environments. The abstract does not provide specific numerical data, such as percentages or p-values, from the reviewed RCTs to quantify this limited effectiveness.
Crucially, the analysis also highlighted a significant gap: there were no large, recent trials specifically investigating TXA for the treatment of established PPH in HICs. The existing evidence primarily focused on prevention, and even in that context, the observed benefit was minimal or absent, indicating that the clinical utility of TXA for PPH prevention in HIC populations may not align with its efficacy in LMICs.
Key Findings
- Tranexamic acid (TXA) shows limited to no effectiveness for postpartum hemorrhage (PPH) prevention in high-income countries (HICs).
- Evidence for TXA's PPH prevention in HICs contrasts with established benefits observed in low- and middle-income countries (LMICs).
- No large, recent randomized controlled trials (
RCTs) exist on TXA for PPH treatment in HICs.
Why It Matters
This review challenges the universal applicability of Tranexamic acid (TXA) for postpartum hemorrhage (PPH) prevention across all global settings. For clinicians and healthcare systems in high-income countries, this suggests a critical need to re-evaluate current PPH prevention protocols that might rely on TXA based on evidence primarily derived from LMICs. It implies that the patient profiles, underlying causes of PPH, or existing obstetric care standards in HICs may diminish TXA's impact. Furthermore, the lack of recent large RCTs on TXA for PPH treatment in HICs highlights a critical knowledge gap, meaning that evidence-based guidelines for managing active PPH in these regions may be incomplete. This calls for more targeted research to clarify TXA's role and optimize its use in HIC populations, potentially focusing on specific high-risk subgroups not adequately represented in previous trials, such as those with placenta previa.
tranexamic-acid
postpartum-hemorrhage
maternal-health
review
high-income-countries
obstetrics